These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18291508)

  • 21. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial.
    Kim MB; Chen MH; de Castro M; Loffredo M; Kantoff PW; D'Amico AV
    Cancer; 2013 Sep; 119(18):3280-6. PubMed ID: 23798006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
    Szende B; Romics I; Torda I; Bély M; Szegedi Z; Lovász S
    Urol Int; 1999; 63(2):115-9. PubMed ID: 10592500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.
    Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS
    J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
    Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.
    Patel AA; Chen MH; Renshaw AA; D'Amico AV
    JAMA; 2007 Oct; 298(13):1533-8. PubMed ID: 17911498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
    Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate.
    D'Amico AV; Denham JW; Bolla M; Collette L; Lamb DS; Tai KH; Steigler A; Chen MH
    Cancer; 2007 May; 109(10):2004-10. PubMed ID: 17397033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
    D'Amico AV; Renshaw AA; Sussman B; Chen MH
    JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.
    Liauw SL; Pitroda SP; Eggener SE; Stadler WM; Pelizzari CA; Vannier MW; Oto A
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):378-84. PubMed ID: 22717242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
    Che M; DeSilvio M; Pollack A; Grignon DJ; Venkatesan VM; Hanks GE; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1117-23. PubMed ID: 17689883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
    Copp H; Bissonette EA; Theodorescu D
    Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
    Horwitz EM; Bae K; Hanks GE; Porter A; Grignon DJ; Brereton HD; Venkatesan V; Lawton CA; Rosenthal SA; Sandler HM; Shipley WU
    J Clin Oncol; 2008 May; 26(15):2497-504. PubMed ID: 18413638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed.
    Ornstein DK; Smith DS; Andriole GL
    Urology; 1998 Dec; 52(6):1094-7. PubMed ID: 9836561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.